SG11201912163WA - Compositions and methods for cancer therapy with dengue virus and dendritic cells - Google Patents

Compositions and methods for cancer therapy with dengue virus and dendritic cells

Info

Publication number
SG11201912163WA
SG11201912163WA SG11201912163WA SG11201912163WA SG11201912163WA SG 11201912163W A SG11201912163W A SG 11201912163WA SG 11201912163W A SG11201912163W A SG 11201912163WA SG 11201912163W A SG11201912163W A SG 11201912163WA SG 11201912163W A SG11201912163W A SG 11201912163WA
Authority
SG
Singapore
Prior art keywords
compositions
methods
dendritic cells
cancer therapy
dengue virus
Prior art date
Application number
SG11201912163WA
Inventor
Bruce W Lyday
Tony Chen
Original Assignee
Primevax Immuno Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primevax Immuno Oncology Inc filed Critical Primevax Immuno Oncology Inc
Publication of SG11201912163WA publication Critical patent/SG11201912163WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11201912163WA 2017-06-15 2018-06-14 Compositions and methods for cancer therapy with dengue virus and dendritic cells SG11201912163WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762520345P 2017-06-15 2017-06-15
PCT/US2018/037616 WO2018232166A1 (en) 2017-06-15 2018-06-14 Compositions and methods for cancer therapy with dengue virus and dendritic cells

Publications (1)

Publication Number Publication Date
SG11201912163WA true SG11201912163WA (en) 2020-01-30

Family

ID=64660234

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912163WA SG11201912163WA (en) 2017-06-15 2018-06-14 Compositions and methods for cancer therapy with dengue virus and dendritic cells

Country Status (11)

Country Link
US (1) US20200121745A1 (en)
EP (1) EP3638303A4 (en)
JP (1) JP2020527540A (en)
KR (1) KR20200023375A (en)
CN (1) CN110996997A (en)
AU (1) AU2018285525A1 (en)
EA (1) EA201992863A1 (en)
IL (1) IL271442A (en)
MX (1) MX2019015194A (en)
SG (1) SG11201912163WA (en)
WO (1) WO2018232166A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202016008300U1 (en) 2015-07-02 2017-07-14 PrimeVax Immuno-Oncology, Inc. Compositions for combination therapy with dengue virus and dendritic cells
MX2018003757A (en) 2015-09-26 2018-09-21 Primevax Immuno Oncology Inc Compositions and methods for producing dendritic cells.
CN110139671A (en) 2016-11-16 2019-08-16 普莱瓦克斯免疫肿瘤学公司 Combination immunotherapy for treating cancer
CN116546999A (en) * 2020-09-27 2023-08-04 深圳华大生命科学研究院 Pharmaceutical composition, preparation method and application thereof
CN116333969A (en) * 2023-02-01 2023-06-27 宁波荣安生物药业有限公司 Vero cell culture method for rabies virus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2872199A (en) * 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
US6524587B1 (en) * 1998-05-05 2003-02-25 Bruce W. Lyday Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
WO2000057907A2 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
DE202016008300U1 (en) * 2015-07-02 2017-07-14 PrimeVax Immuno-Oncology, Inc. Compositions for combination therapy with dengue virus and dendritic cells
MX2018003757A (en) * 2015-09-26 2018-09-21 Primevax Immuno Oncology Inc Compositions and methods for producing dendritic cells.
WO2018129202A1 (en) * 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus

Also Published As

Publication number Publication date
US20200121745A1 (en) 2020-04-23
EA201992863A1 (en) 2020-05-06
AU2018285525A1 (en) 2020-01-30
JP2020527540A (en) 2020-09-10
KR20200023375A (en) 2020-03-04
EP3638303A1 (en) 2020-04-22
CN110996997A (en) 2020-04-10
IL271442A (en) 2020-01-30
MX2019015194A (en) 2020-08-03
EP3638303A4 (en) 2021-03-10
WO2018232166A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
HK1253674A1 (en) Compositions and methods for transient gene therapy with enhanced stability
HK1244826A1 (en) Methods and compositions for adoptive cell therapy
IL258688A (en) Compositions and methods for viral cancer neoepitopes
GB201609438D0 (en) Compositions and methods for cell targeted HPV treatment
HK1244493A1 (en) Combination therapy with coagulation factors and multispecific antibodies
IL271442A (en) Compositions and methods for cancer therapy with dengue virus and dendritic cells
EP3166640A4 (en) Combination therapy compositions and methods for treating cancers
EP3331612A4 (en) Methods and compositions for tumor therapy
IL269334A (en) Improved t cell compositions and methods
IL265786A (en) Compositions and methods for enhancing cancer radiotherapy
EP3316897A4 (en) Compositions and methods for combination therapy with dengue virus and dendritic cells
EP3096787A4 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
IL271326A (en) Compositions and methods for enhancing cancer radiotherapy
IL246607B (en) Improved cell compositions and methods for cancer therapy
IL263218A (en) Composition and methods for microbiota therapy
EP3645708A4 (en) Compositions and methods for adoptive cell therapy for cancer
EP3215163A4 (en) Beta-glucan methods and compositions that affect the tumor microenvironment
EP3145516A4 (en) Methods and compositions for treating malignancies with dendritic cells
SI3460052T1 (en) Improved allogeneic dendritic cells for use in cancer treatment
IL271022A (en) Compositions and methods for providing cell replacement therapy
EP3166637A4 (en) Compositions and methods for treating dengue virus infection
ZA202100234B (en) Methods and compositions using recombinant dendritic cells for cancer therapy
EP3565567A4 (en) Compositions and methods for therapy with dengue virus
EP3645020A4 (en) Compositions and methods for adoptive cell therapy
EP3169333A4 (en) Methods and compositions for enhancing cancer therapy